Decision Diagnostics Corp. (OTCMKTS:DECN) Gets Even more Exposure
Decision Diagnostics Corp. (OTCMKTS:DECN) added another 24% to its market value on Friday, as even more investors started hyping about as the end of the week drew near.
There could be little doubt that this latest wave of hype can be attributed to the exposure that the forbes.com and insiderfinancial.com afforded the company. The ticker wasn’t exactly stuck in illiqudity even before the articles hit the web, but the resulting push has taken it to a whole new level on an impressive dollar volume of 830 thousand. Suffice it to say that investors were quite impressed with DECN. But should they have been?
Well, the company’s latest financial report certainly contains very few causes for joy:
- Cash – $627 thousand
- Total current assets – $2.3 million
- Total current liabilities – $1.8 million
- Revenue – $514 thousand
- Net operating loss – $2.4 million
Still, as bad as those numbers are, they do not present the company in a wholly negative light. No, instead, DECN‘s share structure does that.
Suffice it to say that according to the report we just quoted, as of four months ago, DECN had 2000 shares of Series “B” Preferred Stock issued and outstanding. Each and every one of those is convertible into a share of common stock at a rate of one for 15 THOUSAND.
Further, there were 687 MILLION shares of Series “E” convertible stock as well, and each one of those is converting into 14 regular shares of common stock. About 100 million of those were issued during 2015, at rates ranging from $0.19 to $0.25 per share.
Investors would do well to punch those numbers into a calculator, realize that if they so wished, the owners of those series “E” shares could potentially dump on the market nearly 10 BILLION shares of DECN common stock they bought for an adjusted price of about $0.02 each, and think very carefully about that.
